We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 1,100

The Brexit and Patent Law: What You Need to Know
  • Foley & Lardner LLP
  • European Union, United Kingdom, USA
  • August 23 2016

Now that some time has passed since the Brexit vote, some of the ways in which the vote is likely to impact British patent law are becoming clearer


Federal Circuit Affirms Tygacil Formulation Patent
  • Foley & Lardner LLP
  • USA
  • August 23 2016

In Apotex, Inc. v. Wyeth LLC, the Federal Circuit affirmed the decision of the USPTO Patent Trial and Appeal Board (PTAB) finding that Apotex had


Ariosa Loses Verinata Patent Challenge
  • Foley & Lardner LLP
  • USA
  • August 22 2016

Fetal diagnostic pioneer Ariosa Diagnostics lost its latest attempt to invalidate competitor Verinata Health's U.S. Patent No. 8,318,430, "Methods of


USPTO Sued Over December 2015 Holidays
  • Foley & Lardner LLP
  • USA
  • August 18 2016

Elm 3DS Innovations, LLC has sued the USPTO in the U.S. District Court for the Eastern District of Virginia to challenge its authority to declare that


Construing Markush Group Claims
  • Foley & Lardner LLP
  • USA
  • August 16 2016

In Multilayer Stretch Cling Film v. Berry Plastics, the Federal Circuit provided a detailed discussion of the construction of claims that use Markush


Construing Markush Group Claims
  • Foley & Lardner LLP
  • USA
  • August 16 2016

In Multilayer Stretch Cling Film v. Berry Plastics, the Federal Circuit provided a detailed discussion of the construction of claims that use Markush


En Banc Federal Circuit To Review Standards for Amending Claims During AIA Proceedings
  • Foley & Lardner LLP
  • USA
  • August 15 2016

In a rare grant of a petition for rehearing en banc, the court decided that an appeal “warrants en banc consideration” of who bears what burden when


AbbVie Sues Amgen On 10 Of 100 Humira Patents
  • Foley & Lardner LLP
  • USA
  • August 9 2016

On August 4, 2016, AbbVie Inc. filed a complaint against Amgen, Inc. under the Biologics Price Competition and Innovation Act (BPCIA), asserting that


USPTO Launches Patents 4 Patients
  • Foley & Lardner LLP
  • USA
  • August 2 2016

To support the National Cancer Moonshot initiative, the USPTO has launched the Patents 4 Patients program, also known as the Cancer Immunotherapy


The Supreme Court to Tackle Extraterritorial Reach of U.S. Patents
  • Foley & Lardner LLP
  • USA
  • August 1 2016

The Supreme Court recently granted certiorari in Life Techs. Corp. v. Promega Corp., 14-1538, to resolve: “whether a supplier can be held liable